ALNY:NASDAQAlnylam Pharmaceuticals, Inc. Analysis

Alnylam (ALNY) trades at $323.59, just below its 20‑day SMA of $325.92 but well under the 50‑day ($353.32) and 200‑day ($391.55) averages, signaling a bearish price trend. The RSI of 42.5 suggests modest momentum without oversold conditions, while the MACD histogram is positive (+1.33) indicating a short‑term bullish tilt despite the overall bearish direction. Volatility remains high at 37% over the past 30 days and beta is 0.86, reflecting notable price swings that could amplify downside risk. Valuation metrics are extreme: a trailing PE of 138.9 versus an industry average of 25.4, a price‑to‑book of 54.3, and a DCF‑derived fair value of only $36.46, implying the stock is dramatically overvalued at current levels.
Fundamentally, the company delivered near‑$3.7 B in revenue with 85% YoY growth, strong gross margins (81.6%) and a solid operating cash flow of $524 M, underpinned by a robust pipeline that recently gained traction through a Tenaya Therapeutics collaboration and a Freedom Capital Markets upgrade. Forward earnings estimates have surged to $14.54 EPS, compressing the forward PE to 22.3 and supporting a “Buy” consensus from 25 analysts. However, the balance sheet shows a high debt‑to‑equity of 376, and the lack of dividend payout eliminates any income cushion. The mix of high growth potential, overvaluation, and elevated technical risk frames the investment outlook.